Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether EGFR-TKI can control the development of
intracranial lesions in Non Small Cell Lung Cancer patients with asymptomatic brain
metastases, and the difference in progression free survival between exon 19 and exon 21
mutations.